Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- Galux Inc., a South Korean startup...